Ticker

Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao  Teixeira SAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the…

Talphera, Inc. (NASDAQ: TLPH - Get Free Report) insider Shakil Aslam purchased 35,000 shares of the company's stock in a transaction dated Thursday, February 12th. The stock was bought at an average price of $0.81 per share, with a total value of $28,350.00. Following the completion of the transaction, the insider directly owned 83,178 shares of

Talphera, Inc. (NASDAQ: TLPH - Get Free Report) insider Badri Dasu purchased 35,000 shares of the business's stock in a transaction on Thursday, February 12th. The shares were purchased at an average cost of $0.81 per share, for a total transaction of $28,350.00. Following the transaction, the insider owned 76,230 shares of the company's stock, valued

Talphera, Inc. (NASDAQ: TLPH - Get Free Report) CFO Raffi Asadorian acquired 45,000 shares of the company's stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average cost of $0.81 per share, for a total transaction of $36,450.00. Following the acquisition, the chief financial officer owned 91,256 shares in

Talphera, Inc. (NASDAQ: TLPH - Get Free Report)'s share price fell 0.3% on Thursday. The company traded as low as $0.7808 and last traded at $0.8079. 39,878 shares traded hands during trading, a decline of 77% from the average session volume of 173,561 shares. The stock had previously closed at $0.81. Analysts Set New Price